+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Breast Cancer Screening Tests Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4787447
  • Report
  • Region: North America, United States
  • 70 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Agendia BV
  • Hologic Inc.
  • Myriad Genetics
  • QIAGEN NV
  • Siemens Healthineers
  • MORE
Market Overview

The major factors for the growth of North America breast cancer screening tests market include the rising incidence of breast cancer, increasing government initiatives and support, and technological advancements.

Breast cancer is currently the leading cause of cancer-related deaths in women in North America. According to the American Cancer Society, in 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed among women. In addition, 63,410 cases of in situ breast carcinoma were diagnosed among women. Approximately 40,610 women and 460 men died from breast cancer in 2017 and furthermore, the number of breast cancer cases are expected to increase in the coming years. Moreover, it is estimated that the risk of an individual dying from breast cancer would increase in the coming years. Hence, the increase in breast cancer prevalence is a major factor contributing to the revenue growth of the breast cancer screening tests market. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of this report, breast cancer screening is carried out to detect cancer in its early stages and ensure the timely treatment to the patients. There are different types of breast cancer depending on the type of breast cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes. The market is segmented by test and geography.

Key Market Trends

Mammograms are the Segment by Imaging Test is expected to Hold the Largest Market Share

In most of the cases of breast cancer screening, mammograms are used. The United States Preventive Services Task ForceExternal (USPSTF) recommends that women who are 50 to 74 years old and are at average risk for breast cancer get a mammogram every two years. Furthermore, mammograms are the best way to find breast cancer early, and having regular mammograms can lower the risk of dying from breast cancer. At this time, a mammogram is the best way to find breast cancer for most women. However, there are other imaging techniques which are also gaining more popularity over the forecast period. Also, mammography is less likely to find breast tumors in women with dense breast tissue as both tumors and dense breast tissue appear white on a mammogram, it can be harder to find a tumor when there is dense breast tissue. Thus, owing to the rising cases of breast cancer in the region the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a moderately fragmented market owing to the presence of several small and major market players. Some of the market players are Agendia BV, Fujifilm Holdings Corporation, Hologic Inc., Metabolomic Technologies Inc., Myriad Genetics, QIAGEN NV, Quest Diagnostics Incorporated, and Siemens Healthineers


As part of this package, any purchases made up to 30th June will receive the following:

1) Free update of the report in 6 months on request
2) Free Market Estimate sheet excel data sheet
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agendia BV
  • Hologic Inc.
  • Myriad Genetics
  • QIAGEN NV
  • Siemens Healthineers
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Breast Cancer
4.2.2 Increasing Government Initiatives and Support
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Controversies Related to Mammography
4.3.2 Side-effects of Radiation during Screening Tests and Errors in Screening
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Test
5.1.1 Genomic Tests
5.1.1.1 MammaPrint Test
5.1.1.2 Breast Cancer Index Test
5.1.1.3 Mammostrat Test
5.1.1.4 PAM50 Test
5.1.1.5 Oncotype DX Test
5.1.1.6 Other Genomic Tests
5.1.2 Imaging Test
5.1.2.1 Mammograms
5.1.2.2 Ultrasound
5.1.2.3 MRI
5.1.2.4 Tomography
5.1.2.5 Other Imaging Tests
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agendia BV
6.1.2 Fujifilm Holdings Corporation
6.1.3 Hologic Inc.
6.1.4 Metabolomic Technologies Inc.
6.1.5 Myriad Genetics
6.1.6 QIAGEN NV
6.1.7 Quest Diagnostics Incorporated
6.1.8 Siemens Healthineers

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Agendia BV
  • Fujifilm Holdings Corporation
  • Hologic Inc.
  • Metabolomic Technologies Inc.
  • Myriad Genetics
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers
Note: Product cover images may vary from those shown
Adroll
adroll